Genmab A/S (NASDAQ:GMAB) Sees Strong Trading Volume on Analyst Upgrade

Genmab A/S Sponsored ADR (NASDAQ:GMAB) shares saw an uptick in trading volume on Monday after Wall Street Zen upgraded the stock from a buy rating to a strong-buy rating. 2,317,331 shares were traded during trading, an increase of 61% from the previous session’s volume of 1,440,220 shares.The stock last traded at $28.75 and had previously closed at $29.07.

GMAB has been the subject of a number of other research reports. Truist Financial lifted their price objective on Genmab A/S from $45.00 to $46.00 and gave the company a “buy” rating in a research report on Tuesday, July 8th. HC Wainwright boosted their price target on Genmab A/S from $35.00 to $36.00 and gave the company a “buy” rating in a research note on Friday, August 15th. Guggenheim raised shares of Genmab A/S from a “neutral” rating to a “buy” rating and set a $43.00 price objective on the stock in a research report on Tuesday, September 23rd. Finally, Zacks Research downgraded shares of Genmab A/S from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, August 19th. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $40.00.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Foresight Group Ltd Liability Partnership acquired a new position in Genmab A/S during the 1st quarter worth $954,000. Vident Advisory LLC acquired a new position in shares of Genmab A/S during the 1st quarter worth about $242,000. GAMMA Investing LLC lifted its position in shares of Genmab A/S by 1,465.3% during the 1st quarter. GAMMA Investing LLC now owns 33,482 shares of the company’s stock worth $656,000 after purchasing an additional 31,343 shares during the last quarter. Fifth Third Bancorp boosted its stake in Genmab A/S by 16.6% during the 1st quarter. Fifth Third Bancorp now owns 42,151 shares of the company’s stock valued at $825,000 after purchasing an additional 6,015 shares during the period. Finally, Parallel Advisors LLC grew its holdings in Genmab A/S by 377.5% in the 2nd quarter. Parallel Advisors LLC now owns 3,720 shares of the company’s stock valued at $77,000 after buying an additional 2,941 shares during the last quarter. 7.07% of the stock is currently owned by institutional investors and hedge funds.

Genmab A/S Stock Performance

The company has a market capitalization of $18.82 billion, a P/E ratio of 14.74, a P/E/G ratio of 1.70 and a beta of 0.93. The company has a 50-day simple moving average of $25.11 and a 200 day simple moving average of $22.13.

Genmab A/S (NASDAQ:GMAB) last announced its quarterly earnings data on Thursday, August 7th. The company reported $0.54 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.39 by $0.15. The business had revenue of $925.00 million for the quarter, compared to the consensus estimate of $5.77 billion. Genmab A/S had a net margin of 37.53% and a return on equity of 21.03%. Genmab A/S has set its FY 2025 guidance at EPS. As a group, sell-side analysts forecast that Genmab A/S Sponsored ADR will post 1.45 earnings per share for the current year.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.